New drug R289 offers hope for blood cancer patients who failed other therapies
NCT ID NCT05308264
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 25 times
Summary
This study tests a new drug called R289 in adults with a type of blood cancer called lower-risk myelodysplastic syndromes (MDS) that has not improved with standard treatments. The main goal is to check if R289 is safe and tolerable, and to see if it can reduce or eliminate the need for blood transfusions. About 86 participants will take R289 pills daily, and researchers will monitor side effects and any improvement in blood cell counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOW RISK MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cleveland Clinic
RECRUITINGCleveland, Ohio, 44195, United States
-
Duke Cancer Institute
NOT_YET_RECRUITINGDurham, North Carolina, 27705, United States
-
Ichan School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
-
Intermountain Healthcare
RECRUITINGSalt Lake City, Utah, 84009, United States
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
Mount Sinai Medical Center
WITHDRAWNMiami Beach, Florida, 33140, United States
-
Oncology Clinical Research Referral Office
RECRUITINGHackensack, New Jersey, 07601, United States
-
Rutgers Cancer Institute of New Jersey
WITHDRAWNNew Brunswick, New Jersey, 09083, United States
-
Stanford Cancer Institute
NOT_YET_RECRUITINGPalo Alto, California, 94304, United States
-
The Ohio State University Comprehensive Cancer Center
NOT_YET_RECRUITINGColumbus, Ohio, 43210, United States
-
University of California, Irvine
RECRUITINGOrange, California, 92868, United States
-
University of California, Los Angeles
RECRUITINGLos Angeles, California, 90095, United States
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
-
University of Texas, Southwestern
RECRUITINGDallas, Texas, 75390, United States
-
WashU Medicine
NOT_YET_RECRUITINGSt Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.